Adenosine monophosphate-activated protein kinase and Sirtuin 1 signaling axis (AMPK/SIRT1 axis)

The Adenosine monophosphate-activated protein kinase (AMPK) and Sirtuin 1 (SIRT1) signaling axis is a fundamental regulatory network that integrates cellular energy status with metabolic and epigenetic responses [1, 7]. AMPK serves as a primary energy sensor that is activated by high AMP/ATP ratios, while SIRT1 is an NAD+-dependent deacetylase that responds to nutrient scarcity [7, 12]. These two molecules are functionally linked through a reciprocal positive feedback loop: AMPK activation increases intracellular NAD+ levels by upregulating NAMPT, thereby activating SIRT1, while SIRT1 can deacetylate and activate LKB1, the upstream kinase for AMPK [1, 12]. Together, they coordinate key biological processes such as mitochondrial biogenesis, fatty acid oxidation, and autophagy, primarily through the modulation of downstream effectors like PGC-1alpha and FOXO transcription factors [3, 5, 12]. Dysregulation of the AMPK/SIRT1 axis is strongly associated with the pathogenesis of metabolic disorders, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease, as well as age-related conditions like neurodegeneration and cardiovascular disease [1, 8, 13]. Pharmacological intervention aimed at activating this axis has shown significant therapeutic promise [1, 5]. For instance, metformin, a widely used anti-diabetic drug, acts as an indirect AMPK activator, while natural compounds like resveratrol and synthetic small molecules like SRT1720 target SIRT1 [1, 3, 12]. Despite its therapeutic potential, the axis's involvement in diverse cellular pathways necessitates a nuanced approach, as systemic activation may have tissue-specific effects or influence tumor progression in certain cancer contexts [4, 5, 9].

Other names

AMPK/SIRT1 pathwayAMPK-SIRT1-PGC-1alpha axisAMPK-Nampt-SIRT1 axisSirtuin 1 and AMP-activated protein kinase signaling axis

Drugs targeting this axis typically act as activators of either AMPK or SIRT1, initiating a positive feedback loop where AMPK increases NAD+ levels to stimulate SIRT1 activity, and SIRT1 deacetylates upstream kinases like LKB1 to further activate AMPK [1, 7, 12]. This coordinated activation leads to the deacetylation and activation of downstream targets such as PGC-1alpha, which promotes mitochondrial biogenesis, enhances fatty acid oxidation, and improves glucose homeostasis [1, 3, 5].